GTHP (Guided Therapeutics) EBITDA Margin %: 0.00% (As of Mar. 2026)


GTHP Guided Therapeutics Inc GTHP
18 GF Score
Price $0.24
! 4 Warning Signs
View Full Analysis

What is Guided Therapeutics EBITDA Margin %?

Guided Therapeutics GTHP -7.69% 18 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates GTHP with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Guided Therapeutics ranks worse than 89.95% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Guided Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-0.33 Mil. Guided Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Guided Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.


Guided Therapeutics  (OTCPK:GTHP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Guided Therapeutics EBITDA Margin % Related Terms


Guided Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Guided Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guided Therapeutics EBITDA Margin % Chart

Guided Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,033.33 -28,361.54 -3,189.80 -27,728.57 -322.29

Guided Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -535.90 -976.67 -170.51 0.00

GTHP vs LFWD, VNRX, IRIX: EBITDA Margin % Comparison

For the Medical Devices subindustry, Guided Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guided Therapeutics EBITDA Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Guided Therapeutics's EBITDA Margin % falls into.


GTHP
18GF Score
Guided Therapeutics Inc GTHP
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guided Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Guided Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-2.472/0.767
=-322.29 %

Guided Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.325/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Guided Therapeutics (GTHP) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guided Therapeutics and its competitors. According to the industry distribution chart, Guided Therapeutics ranks #734 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 90%.
Is Guided Therapeutics' EBITDA Margin % too high?
Guided Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Guided Therapeutics ranks #734 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Guided Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Guided Therapeutics' EBITDA Margin % compare to LFWD and VNRX?
According to the Medical Devices & Instruments industry distribution chart, Guided Therapeutics ranks #734 out of 816 companies for EBITDA Margin %. This places Guided Therapeutics in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guided Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guided Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guided Therapeutics stock overvalued right now?
Guided Therapeutics (GTHP) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Guided Therapeutics' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Guided Therapeutics (GTHP), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Guided Therapeutics Business Description

Address 5835 Peachtree Corners East, Suite B, Peachtree Corners, GA, USA, 30092
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and the extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
18GF Score

Get the complete analysis for GTHP

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price